Ifetroban Receives FDA Orphan Drug Designation for Duchenne Muscular Dystrophy-Associated Cardiomyopathy
Key Insights
Ifetroban, a thromboxane-prostanoid receptor (search) antagonist, has been granted Orphan Drug Designation by the FDA for treating cardiomyopathy (search) associated with Duchenne Muscular Dystrophy (search) (DMD).
The FDA also granted Ifetroban Rare Pediatric Disease designation, highlighting the urgent need for targeted therapies for rare conditions affecting children.
Ifetroban is currently under investigation in the FIGHT DMD trial, a double-blind, placebo-controlled study assessing its effectiveness, safety, and pharmacokinetics in DMD patients.
Cumberland Pharmaceuticals (search)' ifetroban, a thromboxane-prostanoid receptor (search) (TPr) antagonist, has received Orphan Drug Designation (ODD) from the FDA for the treatment of cardiomyopathy (search) associated with Duchenne muscular dystrophy (search) (DMD). The FDA also granted ifetroban a Rare Pediatric Disease (RPD) designation, underscoring the critical need for therapies targeting rare childhood conditions.
Clinical Significance
DMD, a devastating genetic disorder primarily affecting young boys, leads to progressive skeletal and cardiac muscle weakness. Cardiomyopathy (search), a major complication of DMD, is a leading cause of mortality in these patients. The ODD and RPD designations for ifetroban aim to accelerate the development of a potential treatment for this life-threatening condition.
AJ Kazimi, CEO of Cumberland Pharmaceuticals (search), stated that these designations are a "critical step forward" and "represent hope for families and a pathway to bring transformative medicines to a vulnerable patient population more quickly and efficiently."
Ongoing Clinical Trial: FIGHT DMD
Ifetroban is currently being evaluated in the FIGHT DMD trial, a 12-month, double-blind, placebo-controlled study. This trial is designed to assess the effectiveness, safety, and pharmacokinetics of oral ifetroban in patients with DMD. The primary focus is to determine if ifetroban can mitigate fibrosis (search), a process where normal heart tissues are replaced by scar tissue, a common occurrence in DMD patients.
Mechanism of Action and Pre-clinical Evidence
Ifetroban functions by exhibiting high affinity for TPr on various cell types, including platelets, cardiomyocytes, vascular and airway smooth muscle, and fibroblasts, without demonstrating agonistic activity. Pre-clinical studies in muscular dystrophy models, including DMD, have indicated that ifetroban can prevent cardiac dysfunction and fibrosis (search), potentially improving mortality rates. Animal models have demonstrated that oral ifetroban can prevent scarring in the heart and improve survival outcomes compared to placebo.
Broader Applications
Beyond DMD, ifetroban is also being investigated for its potential in treating systemic sclerosis and pulmonary fibrosis (search). The FIGHTING FIBROSIS trial, a multicenter, randomized, placebo-controlled phase 2 study, is enrolling patients with idiopathic pulmonary fibrosis (search) (IPF), a progressive lung disease characterized by inflammation and fibrosis of the lungs. There is currently no cure for IPF, and fibrosis can lead to rapidly declining lung function and reduced survival within 5 years of diagnosis.
Disease Burden
DMD affects approximately 1 in every 3300 male births worldwide. This rare and fatal genetic disorder is characterized by mutations in the gene responsible for producing dystrophin, leading to damage in both skeletal and cardiac muscle. The FDA's decision to grant ODD and RPD to ifetroban underscores the urgent need for effective treatments to combat cardiomyopathy (search), the primary cause of death in DMD patients.